Skip to content

Application of Nano carbon tracer in diagnosis of transversely colon cancer with outside mesenteric lymph nodes metastasis Informed Consent

Application of Nano carbon tracer in diagnosis of transversely colon cancer with outside mesenteric lymph nodes metastasis Informed Consent

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028054
Enrollment
Unknown
Registered
2019-12-08
Start date
2018-01-01
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transverse colon cancer

Interventions

Case series:Application of Nano carbon tracer

Sponsors

Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. Colonoscopy biopsy pathological diagnosis of colorectal adenocarcinoma; 3. Good heart, lung, liver and kidney functions, suitable for surgery; 4. Abdominal MRI showed that the tumor was located in the transverse colon, i.ecT2-T4N+M0; 5. informed consent; 6. Body Mass Index (BMI, Body Mass Index) 18-30kg/m.

Exclusion criteria

Exclusion criteria: 1. cT1 / N0. 2. Emergency surgery for acute intestinal obstruction, bleeding, perforation, etc. 3. multiple primary colorectal malignancies or tumors of other organs 4. Familial adenomatous polyposis (FAP), Lynch syndrome, inflammatory bowel disease 5. American society of anesthesiologists (ASA) grade greater than III 6. Patients with severe heart, lung, liver and kidney diseases who cannot tolerate endoscopic surgery 7. Poor general condition, which cannot be corrected and improved despite preoperative treatment 8. Pregnancy and lactation 9. Patients or their families cannot understand the conditions and objectives of this study 10. Those deemed by the researcher to be unfit for enrolment; 11. With history of other malignant tumors (except for properly treated basal cell carcinoma); 12. With preoperative chemotherapy.

Design outcomes

Primary

MeasureTime frame
No4 4 lymph nodes;No6 lymph nodes;

Countries

China

Contacts

Public ContactYing Huang

Fujian Medical University Union Hospital

hy13365910923@163.com+86 13365910923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026